Give the gift of LIFE! Support the Population Research Institute!


Topics: OTC

a woman in thought

USAID Needs to Warn Women of the Dangers of Depo-Provera

  Despite mounting evidence of serious side effects associated with the use of injectable contraceptives, international aid programs continue to indiscriminately distribute Depo-Provera under various brand names worldwide. Indeed, a coalition of family planning partners including the United States Agency for International Development (USAID), the Bill and Melinda Gates Foundation, PATH (Program for Appropriate Technology in Health), and others are seeking to inject even more vulnerable women in developing countries with risky injectable contraceptives. Like …

Read more.

FDA Prepares Sell-Out on MAP

11 Aug 2006     Vol. 8 / No. 31 FDA Prepares Sell-Out on MAP After resisting for years feminists determined to make high-dosage steroids available to women and girls without a prescription, it seems that the Bush Administration is about to cave in to political pressure and make the morning-after pill (MAP) accessible over the counter to those over 18.  Not only will this result in the deaths of more unborn children since MAP often acts after …

Read more.

OTC/MAP Means Danger for American Girls

April 16, 2004 Volume 6 / Number 15 Dear Colleague: Over-the-counter (OTC) availability of the morning-after pill (MAP)-so called “emergency contraception” or EC- would increase rates of abortion, disease, sexual promiscuity, and sexual violence committed against American teens. OTC/MAP means danger for American girls. Steven W. Mosher President ACTION ITEM: Email  Say “I urge the FDA to not approve the morning-after pill for over-the-counter distribution (2001P-0075), because doing this would cause increased rates of promiscuity, abortion …

Read more.

New Report on FDA Approval of ‘Emergency Contraception’

Press Release Source: Population Reseach New Report on FDA Approval of ‘Emergency Contraception’ WASHINGTON, DC, 31 March 2004 — Population Research Institute has released an in-depth report on so-called “emergency contraception.” The U.S. Food and Drug Administration (FDA) has delayed its decision to act on Women’s Capital Corporation/Barr Laboratories application for over-the-counter (OTC) status for so-called “emergency contraception”(EC), the morning-after pill (MAP). Opposition to OTC/MAP involves concerns that OTC/MAP would increase rates of rape, STDs, …

Read more.

Never miss an update!

Get our Weekly Briefing! We send out a well-researched, in-depth article on a variety of topics once a week, to large and growing English-speaking and Spanish-speaking audiences.